After nearly six decades of failed attempts, the first RSV vaccines for older adults finally arrived in 2023, and they could not have come at a more critical moment. The FDA approved GSK’s Arexvy and Pfizer’s Abrysvo in May 2023 for adults aged 60 and older, followed by Moderna’s mRNA-based mResvia in June 2024. These three vaccines now give seniors a real defense against a virus that hospitalizes an estimated 60,000 to 160,000 older Americans and kills between 6,000 and 10,000 every year. For families navigating dementia care, where a respiratory hospitalization can trigger rapid cognitive decline and delirium, this breakthrough carries particular weight.
Yet the uptake has been alarmingly low. By December 2024, only 34 percent of adults 75 and older had received an RSV vaccine, and just 31 percent of high-risk adults aged 60 to 74 had rolled up their sleeves. That means roughly two-thirds of the people most vulnerable to severe RSV illness remain unprotected heading into the 2025–2026 season, which has already seen an early surge in cases. For caregivers managing loved ones with cognitive impairment, chronic lung disease, or weakened immune systems, understanding this vaccine is not optional — it is urgent. This article covers what RSV actually does to aging bodies and brains, how the three available vaccines compare, what the real-world effectiveness data show after two full seasons, the rare but serious safety concern involving Guillain-Barré syndrome, what it costs, and why the current RSV season demands attention right now.
Table of Contents
- Why Did It Take 60 Years to Get an RSV Vaccine for Seniors?
- How the Three RSV Vaccines Compare — and Where Each Falls Short
- What Caregivers of Dementia Patients Need to Know About RSV Risk
- Timing, Cost, and Getting the RSV Vaccine Without Barriers
- The Guillain-Barré Syndrome Warning — What It Means in Practice
- Why the 2025–2026 RSV Season Demands Attention Now
- What Comes Next for RSV Prevention in Older Adults
- Conclusion
- Frequently Asked Questions
Why Did It Take 60 Years to Get an RSV Vaccine for Seniors?
Respiratory syncytial virus has been a known threat since the 1960s, when the NIH first attempted to develop a vaccine against it. That early effort ended in disaster — a formalin-inactivated vaccine candidate actually made the disease worse in children who were later exposed to the virus, a phenomenon called vaccine-enhanced disease. The failure haunted RSV research for decades and made pharmaceutical companies deeply cautious about pursuing new candidates. It was not until advances in structural biology allowed scientists to stabilize the RSV F protein in its prefusion form that a viable path forward emerged. The timing of the 2023 approvals matters for another reason.
Broader estimates suggest that RSV causes approximately 4.3 million symptomatic infections, 172,000 hospitalizations, 31,000 ICU admissions, and 15,000 deaths annually among adults aged 60 and older in the United States alone. These are not fringe numbers. RSV rivals influenza as a killer of older adults, yet until two years ago, there was no vaccine, no antiviral, and no real public awareness that the virus posed this level of danger. For people living with dementia or other neurodegenerative conditions, RSV carries a compounding risk. Hospitalization in older adults with cognitive impairment frequently triggers delirium, accelerates functional decline, and can lead to permanent loss of independence. A vaccine that prevents even a fraction of those hospitalizations has outsized value in this population — not just for survival, but for preserving quality of life.
How the Three RSV Vaccines Compare — and Where Each Falls Short
All three vaccines target the same protein on the RSV virus — the prefusion F protein — but they use different platforms to get there. Arexvy from GSK is an adjuvanted protein-based vaccine. Abrysvo from Pfizer is a bivalent protein vaccine without adjuvant. mResvia from Moderna uses mRNA technology similar to its COVID-19 vaccine. The CDC does not express a preference among the three, meaning any of them is considered an acceptable choice. Real-world effectiveness data have been encouraging. Arexvy showed roughly 77 percent effectiveness against RSV-related emergency department visits and approximately 83 percent effectiveness against hospitalization in adults 60 and older.
Abrysvo was about 79 percent effective against ED visits and 73 percent effective against hospitalizations. One large real-world study estimated 92 percent effectiveness against the worst RSV outcomes. These numbers are strong for a first-generation vaccine against a respiratory virus, though they do not approach the near-total protection that some childhood vaccines provide. However, there is an important caveat about durability. Data from Vanderbilt University showed that a single shot reduced RSV hospitalization risk by 69 percent in the first season but dropped to 48 percent in the second season. That decline is meaningful, and it raises a question the CDC has not yet answered: will boosters eventually be recommended? For now, the guidance calls for one dose with no booster. Caregivers and clinicians should watch for updated recommendations, particularly for immunocompromised individuals and those with dementia, who may mount a weaker initial immune response.
What Caregivers of Dementia Patients Need to Know About RSV Risk
Consider a common scenario in memory care: a resident develops what looks like a bad cold. Within days, the cough deepens, oxygen levels dip, and a trip to the emergency room follows. The culprit is often RSV, but because most hospitals did not routinely test for it until recently, many of these cases were attributed to influenza or pneumonia. The result was that RSV flew under the radar as a major threat to older adults in congregate settings. Dementia compounds every dimension of RSV illness.
Patients with cognitive impairment are less likely to report symptoms accurately, more likely to aspirate secretions due to swallowing difficulties, and far more likely to experience delirium during hospitalization. Studies have repeatedly shown that even a single hospitalization for an acute illness can shift a dementia patient from one functional stage to another, a decline that does not reverse when the infection clears. The virus itself may pass, but the damage to independence and cognition often does not. This is precisely why vaccination matters disproportionately for this population. A caregiver who ensures their loved one receives an RSV vaccine before the season begins is not just preventing a respiratory infection — they are potentially preventing a cascade of cognitive and functional losses that no amount of rehabilitation can fully undo.
Timing, Cost, and Getting the RSV Vaccine Without Barriers
The CDC recommends that all adults aged 75 and older receive a single dose of RSV vaccine, along with adults aged 50 to 74 who face increased risk due to chronic conditions, immunocompromission, or living in congregate settings like nursing homes. The best window for vaccination is late summer or early fall, before RSV season begins, though the vaccine can be administered at any point. Cost should not be a barrier for most seniors. Medicare Part D covers the RSV vaccine at zero out-of-pocket cost — no copay, no deductible. This is a direct result of the Inflation Reduction Act’s vaccine provisions, which eliminated cost-sharing for all recommended adult vaccines under Part D starting in 2023. For those without insurance, the picture is less forgiving: out-of-pocket prices range from $157 to $550 depending on the specific vaccine and pharmacy.
Moderna’s mResvia tends to sit at the higher end of that range, while Pfizer’s Abrysvo is often available at the lower end, though pricing varies by location. The tradeoff for caregivers is largely logistical, not financial. Getting a person with moderate to advanced dementia to a pharmacy appointment requires planning, and some individuals may resist the injection due to confusion or anxiety. Mobile vaccination programs and in-home nursing visits can help. Many long-term care facilities now offer RSV vaccination alongside annual flu shots, which simplifies the process considerably. If your loved one’s facility has not yet incorporated RSV vaccination into its fall immunization protocol, it is worth raising the question directly with their medical director.
The Guillain-Barré Syndrome Warning — What It Means in Practice
Shortly after the RSV vaccines entered broad use, postmarketing surveillance flagged a small but real signal for Guillain-Barré syndrome, a rare neurological condition in which the immune system attacks peripheral nerves. The FDA subsequently required GBS warnings on the labels of both Abrysvo and Arexvy. Estimates place the excess risk at approximately 9 additional GBS cases per million doses of Abrysvo and about 7 per million doses of Arexvy in adults aged 65 and older. To put those numbers in perspective, the United Kingdom reported 21 suspected GBS cases out of more than 1.9 million Abrysvo doses administered. That translates to roughly 1 in 90,000 — a real risk, but a rare one.
No RSV vaccine has been withdrawn from the market, and both the CDC and international regulators have concluded that the benefits of vaccination outweigh the GBS risk for the recommended populations. The calculus is straightforward: RSV kills thousands of older Americans annually, while GBS following vaccination, though serious, is uncommon and most patients recover. That said, the warning deserves honest consideration, particularly for individuals who have a history of GBS or other autoimmune neurological conditions. If a dementia patient has previously experienced GBS or has an active autoimmune disorder, their physician should weigh the individual risk-benefit ratio carefully. This is not a reason to avoid the vaccine broadly, but it is a reason to have a real conversation with a doctor rather than simply accepting or refusing vaccination based on headlines.
Why the 2025–2026 RSV Season Demands Attention Now
The United States experienced an early surge in RSV activity beginning in late summer 2025, catching many healthcare systems off guard. The CDC projects that peak weekly hospitalizations during the 2025–2026 season will be similar to the 2024–2025 season, and hospitalization rates among adults 65 and older are currently tracking above the historical average. This is not a theoretical concern — it is happening right now.
For caregivers and families, the practical implication is simple: if your loved one has not been vaccinated against RSV, the window to act before peak season is narrowing. The vaccine takes approximately two weeks to reach full effectiveness, so every week of delay is a week of unnecessary exposure. Given that only about 16.4 percent of adults aged 60 and older — roughly 12.8 million people — received the vaccine between August 2023 and February 2025, the vast majority of older Americans remain unprotected. In congregate living settings where dementia patients are concentrated, one unvaccinated resident with RSV can trigger an outbreak that affects dozens.
What Comes Next for RSV Prevention in Older Adults
The RSV vaccine landscape is still evolving rapidly. In 2025, the FDA expanded the approved age ranges for both Arexvy (now approved for adults 18 to 49 at increased risk) and mResvia (now approved for adults 18 to 59 at increased risk). These expansions suggest that regulators and manufacturers see RSV vaccination as a broader public health tool, not just a measure for the elderly. For the dementia care community, this could eventually mean that younger caregivers and family members can also be vaccinated, creating a protective ring around vulnerable individuals.
The open question is durability. With effectiveness declining from 69 percent to 48 percent between the first and second RSV seasons after a single dose, the discussion around booster doses will likely intensify over the coming years. Researchers are also exploring whether combining RSV vaccination with influenza and COVID-19 vaccines in a single visit could improve uptake, which currently remains stubbornly low. For now, the evidence is clear that one shot provides meaningful protection, and the best time to get it is before the season peaks — not after a loved one is already in the hospital.
Conclusion
The arrival of RSV vaccines for older adults represents one of the most significant advances in geriatric preventive medicine in years. Three vaccines — Arexvy, Abrysvo, and mResvia — now offer 73 to 92 percent protection against the worst RSV outcomes, are covered by Medicare at no cost, and require only a single dose. For families caring for someone with dementia, these vaccines address a threat that goes beyond respiratory illness: they help prevent the hospitalizations that so often trigger irreversible cognitive and functional decline. The rare GBS risk, while deserving of informed discussion, does not change the fundamental math for the vast majority of older adults.
The gap between what is available and what is being used remains the central problem. With two-thirds of eligible seniors still unvaccinated and the 2025–2026 RSV season already running above historical averages, the opportunity to protect a vulnerable loved one exists right now — but it will not wait. Talk to your loved one’s physician, contact their pharmacy, or ask their care facility about RSV vaccination before the season peaks. Sixty years of waiting for this vaccine is long enough. The last thing anyone should do now is wait longer.
Frequently Asked Questions
Is the RSV vaccine a yearly shot like the flu vaccine?
No. The current CDC recommendation is for a single dose with no booster. Unlike the flu shot, which must be repeated annually because influenza strains change rapidly, the RSV vaccine provides protection that has been shown to last across at least two seasons, though effectiveness does decline over time from roughly 69 percent in year one to 48 percent in year two.
Can someone with dementia safely receive the RSV vaccine?
Dementia itself is not a contraindication to RSV vaccination. In fact, people with dementia are among those who stand to benefit most because hospitalization poses such an outsized risk to their cognitive function. The primary safety concern — Guillain-Barré syndrome — affects an estimated 7 to 9 people per million doses and is not related to cognitive status. Discuss any history of autoimmune conditions with the prescribing physician.
Does Medicare cover the RSV vaccine?
Yes. Medicare Part D covers all three RSV vaccines at zero out-of-pocket cost, meaning no copay and no deductible. This applies regardless of which of the three vaccines is administered. Without insurance, costs range from $157 to $550 depending on the vaccine and pharmacy.
Which RSV vaccine is best for older adults?
The CDC does not recommend one over the others. Arexvy showed approximately 83 percent effectiveness against hospitalization, Abrysvo showed about 73 percent, and all three target the same viral protein. The practical choice often comes down to which vaccine is available at your pharmacy or care facility. If your loved one has a history of strong reactions to mRNA vaccines, the protein-based options may be preferred, though this should be discussed with a doctor.
When is the best time to get the RSV vaccine?
Late summer or early fall, before RSV season begins in earnest. The vaccine takes about two weeks to reach full effectiveness. Given that the 2025–2026 season saw an early surge starting in late summer, earlier vaccination is better. However, getting vaccinated later in the season still provides meaningful protection.
Should caregivers also get the RSV vaccine?
As of 2025, the FDA has expanded approval for Arexvy to adults 18–49 at increased risk and mResvia to adults 18–59 at increased risk. Caregivers who have chronic lung or heart conditions, are immunocompromised, or live with a high-risk individual may qualify. Healthy younger caregivers are not yet included in the recommendations, though this may change as the vaccine programs mature.
